Pandemic treatments on trial: the bigger picture. N of many thinking in an N of one scenario

摘要

That the above two quotes are arguably truer now than at the time they were written is perhaps surprising. That this truth resonates equally for the authors who have experienced the two most recent respiratory infection pandemics (H1N1/09 influenza and coronavirus disease 2019 (COVID-19)) and the ongoing bias towards relatively small, uncontrolled treatment trials from very different perspectives, across, between and within hemispheres, countries, healthcare systems, socio-economic-political cultures, populations and individuals [1–6], is even more so.